Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 11/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10173286 | 1.00 | CA4 (0.50) | CA4KIF11KCNH2LTA4HALDH1A1 | |
| SCHEMBL10310990 | 0.93 | KIF11 (0.54) | CA4KIF11KCNH2LTA4HALDH1A1 | |
| SCHEMBL13347465 | 0.92 | CA1 (0.52) | CA4LTA4HALDH1A1CA12CA1 | |
| SCHEMBL23426239 | 0.91 | KIF11 (0.43) | CA4KIF11KCNH2LTA4HALDH1A1 | |
| SCHEMBL22021415 | 0.91 | ESR2 (0.48) | CA4KIF11KCNH2LTA4HALDH1A1 | |
| SCHEMBL22278846 | 0.88 | KIF11 (0.41) | CA4KIF11KCNH2LTA4HALDH1A1 | |
| SCHEMBL18288607 | 0.87 | KIF11 (0.47) | KIF11KCNH2LTA4HKMT2A | |
| SCHEMBL22402881 | 0.82 | CYP2D6 (0.46) | ALDH1A1 | |
| SCHEMBL23960484 | 0.82 | ABL1 (0.42) | KIF11KCNH2 | |
| SCHEMBL18902445 | 0.82 | KIF11 (0.47) | CA4KIF11KCNH2LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024006927-A1 | COMPOSITIONS, KITS, AND METHODS FOR DETECTING NUCLEIC ACIDS USING INTRA-CHANNEL MULTIPLEXING | Life Technologies Corporation (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-11827931-B2 | Methods of preparing growing polynucleotides using nucleotides with 3′ AOM blocking group | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-11-28 | — | — | US | disclosed |
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230257827-A1 | CONJUGATES AND PREPARATION AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257827-A1 | CONJUGATES AND PREPARATION AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-11660347-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-05-30 | — | — | US | disclosed |
| US-20230132756-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7632932-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7579451-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7566775-B2 | N8- and C8-linked purine bases and structurally related heterocycles as universal nucleosides used for oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | RNASEH1, RNASE1, DNASE1 | CA4 2919/4885KIF11 2439/4885KCNH2 3636/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | CA4 2075/4885KIF11 2519/4885KCNH2 3514/4885 |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | CA4 97/4885KIF11 3254/4885KCNH2 3517/4885 |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | DUT, NOP58, DPYD | CA4 2862/4885KIF11 3387/4885KCNH2 4187/4885 |
| US-11660347-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | APOB, C1QBP, APOL1 | CA4 4152/4885KIF11 1953/4885KCNH2 4474/4885 |
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | APOB, C1QBP, APOL1 | CA4 4152/4885KIF11 1953/4885KCNH2 4474/4885 |
| US-20230132756-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF | POLN, POLM, DUT | CA4 1750/4885KIF11 764/4885KCNH2 4793/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | CA4 3164/4885KIF11 3873/4885KCNH2 4475/4885 |
| US-11827931-B2 | Methods of preparing growing polynucleotides using nucleotides with 3′ AOM blocking group | PCNA, NOP2, POLRMT | CA4 2226/4885KIF11 3681/4885KCNH2 3616/4885 |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | NT5C3B, DERA, DUT | CA4 2668/4885KIF11 3607/4885KCNH2 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.